Search Results for: Aducanumab

By Kuldip K. Ambastha Biogen Inc. (BIIB), a biotech company, had a memorable Monday of this past trading week. On Monday, June 7, 2021, Biogen had a +38.3% gain for the day on its stock. Biogen’s Alzheimer’s disease treatment was approved by the U.S. Food and Drug Administration (FDA) as part of an accelerated approval …

Continue reading “What Caught Our Attention in the Investment World? – Week of June 7-11, 2021”

By Kuldip K. Ambastha and Anil K. Ambastha On October 22, 2019, Biogen Inc. (BIIB) delivered a 26.1% return for the day. This was the stock’s largest one-day percentage return in 23 years. Its Alzheimer’s drug (aducanumab) had previously been written off as a failure, but now will be getting a second chance at approval …

Continue reading “What Caught Our Attention in the Investment World? – Week of October 21-25, 2019”